Recent Updates — IPHYF

AstraZeneca has updated the expected timing for the high-level data readout of the PACIFIC-9 Phase 3 trial to the first half of 2027, shifting from the previously anticipated second half of 2026. The revised schedule reflects the event-driven nature of the study, which is currently complete in enrollment. The trial evaluates durvalumab combined with monalizumab or oleclumab in patients with unresectable Stage III non-small cell lung cancer who have not progressed following platinum-based chemoradiation therapy. Monalizumab is an anti-NKG2A antibody developed by Innate Pharma, for which AstraZeneca holds full oncology rights under a co-development agreement initiated in 2015 and finalized in October 2018. Innate Pharma S.A. is a global clinical-stage biotechnology company developing immunotherapies for cancer patients.

Innate Pharma S.A. completed a private placement of 17,647,059 new ordinary shares at €1.70 per share on August 18, 2026, raising approximately €30.0 million in gross proceeds and €27.6 million net after expenses. The capital increase was executed without preferential subscription rights for existing shareholders pursuant to shareholder resolutions from May 21, 2026. Proceeds will primarily fund the clinical development of IPH4502 and advance preclinical ADC portfolio candidates. Innate Pharma S.A. operates in the biotechnology industry, focusing on the discovery and development of immunotherapies for cancer.

Innate Pharma completed enrollment in the Phase 1 dose escalation study of IPH4502, a Nectin-4 exatecan antibody-drug conjugate (ADC). The study included 76 patients across France and the United States. Preliminary data readout from these patients is expected by year-end 2026 to guide dose optimization. Early observations indicate a favorable safety profile with limited hematological toxicity and objective responses in patients with urothelial carcinoma, non-small cell lung cancer, and head and neck squamous cell carcinoma. Innate Pharma is a biotechnology company developing immunotherapies for cancer patients.